Literature DB >> 12518992

The phosphatidylinositol-3 kinase pathway is not essential for insulin-like growth factor I receptor-mediated clonogenic radioresistance.

Yu Dong1, Hiroshi Watanabe, Hitoshi Shibuya, Masahiko Miura.   

Abstract

The insulin-like growth factor I receptor (IGF-IR) is known to induce clonogenic radioresistance in cells following ionizing irradiation. To explore the downstream signaling pathways, we focused on the phosphatidylinositol-3 kinase (PI3-K) pathway, which is thought to be the primary cell survival signal originating from the receptor. For this purpose, R- cells deficient in the endogenous IGF-IR were used as a recipient of the human IGF-IR with or without mutations at potential PI3-K activation sites: NPXY950 and Y1316XXM. Mutants with double mutation at Y950/Y1316 exhibited not abrogated, but reduced activation of IRS-1, PI3-K, and Akt upon IGF-I stimulation. However, the mutants had the same clonogenic radioresistance as cells with wild type (WT) receptors. Neither wortmannin nor LY294002, specific inhibitors of PI3-K, affected the radioresistance of cells with WT receptors at concentrations specific for PI3-K. Collectively, these results indicate that the PI3-K pathway is not essential for IGF-IR-mediated clonogenic radioresistance.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12518992     DOI: 10.1269/jrr.43.325

Source DB:  PubMed          Journal:  J Radiat Res        ISSN: 0449-3060            Impact factor:   2.724


  2 in total

1.  Role of IGF-1/IGF-1R in regulation of invasion in DU145 prostate cancer cells.

Authors:  Zeina Saikali; Hemani Setya; Gurmit Singh; Sujata Persad
Journal:  Cancer Cell Int       Date:  2008-07-03       Impact factor: 5.722

2.  miRNA-214 modulates radiotherapy response of non-small cell lung cancer cells through regulation of p38MAPK, apoptosis and senescence.

Authors:  H Salim; N S Akbar; D Zong; A H Vaculova; R Lewensohn; A Moshfegh; K Viktorsson; B Zhivotovsky
Journal:  Br J Cancer       Date:  2012-08-28       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.